Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Caris Life Sciences, Inc.
CAI
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.3B
$18.30
▼ -2.40%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$14.19 - $42.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 29.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI and machine learning algorithms for molecular data interpretation
- Comprehensive molecular profiling platform covering multiple cancer types
- Strategic partnerships with major biopharmaceutical companies
- Established clinical evidence base supporting treatment recommendations
Bear Case
2 risks
- Low volatility (beta 0.8).
- Growth premium of 2.4x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Growth
Turning profitable
Increasing adoption of precision medicine and personalized cancer treatment
Value
Growth premium of 2.4x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Momentum
Stable
-2.8% over 3m
Quality
Excellent
Emerging growth company (125% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying CAI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 11, 2026
MAY 7, 2026
Reported EPS of -$0.00 vs -$0.02 consensus (+92.5% surprise). Revenue of $216.2M vs $209.4M expected (+3.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+92.5%
Next: Aug 11, 2026
Revenue trend · last 8Q
—
—
—
+50%
+81%
+169%
+193%
+79%
Q3 21
Q1 24
Q2 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$100.8M
$80.7M
$100.0M
$120.9M
$181.4M
$216.8M
$292.9M
$216.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
-0.2%
Wall Street consensus
6 analysts · 83% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
83%
Hold
17%
Sell
0%
Median Price Target
$22.00
▲ +20.2% vs $18.30
Latest: Baird · $22.00 · May 8, 2026
3 analysts covering